13F Holdings
中文EN

LFVN Lifevantage Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%

Margins

Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%

Returns

ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x

Leverage & solvency

Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$182.59M$228.53M$200.16M$213.40M$206.36M
Cost of revenue$40.97M$44.86M$41.44M$43.39M$38.10M
Gross profit$141.61M$183.67M$158.72M$170.01M$168.26M
R&D expense$1.00M$1.40M$700,000$600,000$700,000
SG&A expense$58.42M$69.21M$68.47M$71.06M$63.42M
Operating income$6.10M$12.20M$4.33M$4.26M$7.58M
Interest expense——-$430,000-$198,000$10,000
Pretax income$6.07M$12.24M$4.35M$4.00M$4.69M
Income tax$994,000$2.44M$1.41M$1.46M$1.57M
Net income$5.07M$9.80M$2.94M$2.54M$3.12M
EBITDA$8.87M$15.36M$7.91M$7.84M$10.84M
EPS (basic)0.400.800.240.200.24
EPS (diluted)0.400.750.230.200.24
Dividends declared per share0.180.170.550.120.03
Weighted avg. shares (diluted)12.70M12.99M12.99M12.57M13.07M
Balance sheet
Cash & equivalents$14.92M$20.20M$16.89M$21.61M$20.19M
Receivables$2.99M$3.29M$2.95M$1.61M$3.34M
Inventory$16.17M$20.67M$15.05M$16.07M$16.47M
Current assets$38.30M$50.89M$37.65M$44.28M$46.96M
PP&E, net$7.31M$6.21M$7.81M$9.09M$9.50M
Goodwill$465,000$0———
Intangibles$3.06M$245,000$323,000$455,000$587,000
Total assets$62.11M$71.96M$60.30M$66.12M$70.71M
Current liabilities$20.23M$27.22M$22.31M$19.61M$25.73M
Total liabilities$28.52M$37.32M$34.31M$31.47M$39.19M
Shareholders' equity$33.59M$34.64M$25.99M$34.65M$31.52M
Shares outstanding12.52M12.43M12.51M12.62M12.49M
Cash flow statement
Operating cash flow$10.24M$11.88M$12.20M$6.83M$7.96M
Capital expenditure$3.57M$1.37M$2.25M$3.07M$1.53M
Free cash flow$6.67M$10.51M$9.95M$3.76M$6.43M
Investing cash flow-$7.31M-$1.37M-$2.25M-$3.06M-$1.53M
Financing cash flow-$7.78M-$7.60M-$14.42M-$2.36M-$8.95M
Depreciation & amortization$2.77M$3.16M$3.58M$3.58M$3.26M
Stock-based compensation$2.35M$5.70M$3.28M$3.19M$1.77M
Dividends paid$2.34M$2.07M$6.94M$1.59M$378,000
Share buybacks$2.04M$3.15M$6.43M$822,000$8.83M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.